Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016923
Chunk: 184

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 184
---
 a total number of 2,438,473
warrants were exercised into an equivalent number of shares of Common Stock as compared to no warrants being exercised during the three
months ended March 31, 2024. The proceeds of the exercised warrants for the three months ended March 31, 2025, was $1,414,314,
compared to no
proceeds during the three months ended March 31, 2024.

On February 25, 2025, the Company
entered into a warrant inducement agreement (the “February Inducement Agreement”) with certain holders (the “Holders”)
of the Company’s warrants to purchase shares of the Company’s common stock, issued in a private placement offering that closed
on October 21, 2024 (the “October Warrants”), and a private placement offering that closed on August 5, 2024 (the “August
Warrants” and, together with the October Warrants, collectively, the “Existing Warrants”). Pursuant to the February
Inducement Agreement, the Holders of the Existing Warrants agreed to exercise for cash (i) October Warrants to purchase an aggregate
of up to 1,136,391
shares of Common Stock (the “October Warrant Shares”), at the reduced exercise price of $0.58
per share and August Warrants to purchase an aggregate of up to 1,302,082
shares of Common Stock (the “August Warrant Shares” and, together with the October Warrant Shares, the “Existing Warrant
Shares”), at the reduced exercise price of $0.58
per share. The transactions contemplated by the Inducement Agreement (the “Warrant Inducement”) were consummated on February
26, 2025.

In consideration of the Holders’
immediate exercise of the Existing Warrants in accordance with the February Inducement Agreement, the Company issued unregistered Common
Stock Purchase Warrants (the “New Warrants”) to purchase an aggregate of up to 2,926,166
shares of Common Stock (the “New Warrant Shares”) to the Holders of the Existing Warrants, with an exercise price of $0.85.

In addition, designees of the placement
agent for the Offering were granted warrants to purchase an aggregate of up to 87,785
shares of Common Stock, with an exercise price of $0.85.

The
following table summarizes